Author:
Brown Cameron,Mantzaris Michael,Nicolaou Elpiniki,Karanasiou Georgia,Papageorgiou Elisavet,Curigliano Giuseppe,Cardinale Daniela,Filippatos Gerasimos,Memos Nikolaos,Naka Katerina K.,Papakostantinou Andri,Vogazianos Paris,Ioulianou Erietta,Shammas Christos,Constantinidou Anastasia,Tozzi Federica,Fotiadis Dimitrios I.,Antoniades Athos
Abstract
AbstractBreast cancer patients are at a particularly high risk of cardiotoxicity from chemotherapy having a detrimental effect on quality-of-life parameters and increasing the risk of mortality. Prognostic biomarkers would allow the management of therapies to mitigate the risks of cardiotoxicity in vulnerable patients and a key potential candidate for such biomarkers are microRNAs (miRNA). miRNAs are post-transcriptional regulators of gene expression which can also be released into the circulatory system and have been associated with the progression of many chronic diseases including many types of cancer. In this review, the evidence for the potential application of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity (CIC) in breast cancer patientsis evaluated and a simple meta-analysis is performed to confirm the replication status of each reported miRNA. Further selection of miRNAs is performed by reviewing the reported associations of each miRNA with other cardiovascular conditions. Based on this research, the most representative panels targeting specific chemotherapy agents and treatment regimens are suggested, that contain several informative miRNAs, including both general markers of cardiac damage as well as those for the specific cancer treatments.
Funder
Horizon 2020 Framework Programme
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Oncology
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献